Immune checkpoint inhibitors: immune-related adverse events, healthcare utilization, and costs among commercial and Medicare Advantage patients

BACKGROUND: Immune checkpoint inhibitors (ICI) are increasingly used across multiple cancer types and stages and little is known about real-world outcomes. This study sought to determine healthcare utilization, costs, immune-related adverse events (irAEs), and all-cause mortality of single-agent ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunturu, Krishna S., Pham, Timothy T., Shambhu, Sonali, Fisch, Michael J., Barron, John J., Debono, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942885/
https://www.ncbi.nlm.nih.gov/pubmed/35064328
http://dx.doi.org/10.1007/s00520-022-06826-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942885/
https://www.ncbi.nlm.nih.gov/pubmed/35064328
http://dx.doi.org/10.1007/s00520-022-06826-9

Ejemplares similares